Press release
Vitiligo Pipeline Outlook Report 2025: Key 18+ Companies and Breakthrough Therapies Shaping the Future Landscape
Stay ahead with the latest insights! Download DelveInsight's comprehensive Vitiligo Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Vitiligo Pipeline Outlook Report [https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Vitiligo Pipeline Report
* In August 2025, Incyte Corporation announced a study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
* In July 2025, Clinuvel Inc. conducted a CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone.
* DelveInsight's Vitiligo pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Vitiligo treatment.
* The leading Vitiligo Companies such as Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc . and others.
* Promising Vitiligo Pipeline Therapies such as Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide and others.
Discover how the Vitiligo treatment paradigm is evolving. Access DelveInsight's in-depth Vitiligo Pipeline Analysis for a closer look at promising breakthroughs @ Vitiligo Clinical Trials and Studies [https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Vitiligo Emerging Drugs Profile
* Afamelanotide: Clinuvel, Inc.
Afamelanotide, developed by Clinuvel, Inc., is a synthetic analogue of alpha-melanocyte-stimulating hormone (-MSH) designed to promote skin pigmentation in individuals with vitiligo. It works by activating melanocortin 1 receptors (MC1R) on melanocytes, stimulating melanin production and distribution in depigmented areas of the skin. Afamelanotide is administered via a subcutaneous implant, offering a systemic approach that may enhance repigmentation, particularly when used in combination with controlled UV light therapy. Its mechanism addresses the underlying pigment loss in vitiligo, aiming to restore skin tone more uniformly and effectively. Currently, the drug is in Phase III stage of its development for the treatment of Vitiligo.
* VYN201: Vyne Therapeutics Inc.
Repibresib is a pan-bromodomain BET inhibitor designed to be locally administered as a "soft" drug to address diseases involving multiple, diverse inflammatory cell signaling pathways, while providing low systemic exposure. BET proteins play a key role in regulating gene transcription via epigenetic interactions ("reading"). Recent research has identified a key role for these proteins in regulating activation of immune cells, including T cells and B cells, and subsequent inflammatory and fibrotic processes. As epigenetic readers, BET proteins regulate the recruitment of transcriptional factors that are key to the production of several pro-inflammatory cytokines. BET inhibitors have the potential to treat a range of immuno-inflammatory and fibrotic diseases by blocking pro-inflammatory cytokine transcription, with additional potential in myeloproliferative neoplastic disorders. In addition to demonstrating clinical proof-of-concept in vitiligo, repibresib has produced consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity in several preclinical models (using several different routes of administration). Currently, the drug is in Phase II stage of its development for the treatment of Vitiligo.
* FB102: Forte Biosciences, Inc.
FB102 is a proprietary molecule with potentially broad autoimmune and autoimmune-related applications. The Company's FB102 program aims to address key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. Significant reductions in NK cell pharmacodynamic marker of FB102 mechanism was observed supporting the in vitro as well as the NHP data and mechanism of action of FB102. A phase 1 healthy volunteer SAD/MAD study was successfully completed and demonstrated a good safety profile. Currently, the drug is in Phase I stage of its development for the treatment of Vitiligo.
The Vitiligo Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Vitiligo with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vitiligo Treatment.
* Vitiligo Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Vitiligo Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vitiligo market.
Get a detailed analysis of the latest innovations in the Vitiligo pipeline. Explore DelveInsight's expert-driven report today! @ Vitiligo Unmet Needs [https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Vitiligo Companies
Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc . and others.
Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Vitiligo Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Vitiligo Therapies and key Developments @ Vitiligo Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Vitiligo Pipeline Report
* Coverage- Global
* Vitiligo Companies- Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc . and others.
* Vitiligo Pipeline Therapies- Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide and others.
* Vitiligo Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Vitiligo Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Vitiligo drug development? Find out in DelveInsight's exclusive Vitiligo Pipeline Report-access it now! @ Vitiligo Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Vitiligo: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Vitiligo- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Afamelanotide: Clinuvel, Inc.
* Mid Stage Products (Phase II)
* VYN201: Vyne Therapeutics Inc.
* Early Stage Products (Phase I)
* FB102: Forte Biosciences, Inc.
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Vitiligo Key Companies
* Vitiligo Key Products
* Vitiligo- Unmet Needs
* Vitiligo- Market Drivers and Barriers
* Vitiligo- Future Perspectives and Conclusion
* Vitiligo Analyst Views
* Vitiligo Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=vitiligo-pipeline-outlook-report-2025-key-18-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/vitiligo-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Vitiligo Pipeline Outlook Report 2025: Key 18+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4134145 • Views: …
More Releases from ABNewswire
Liver Cancer Pipeline Outlook Report 2025: Key 70+ Companies and Breakthrough Th …
DelveInsight's, "Liver Cancer Pipeline Insights 2025" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Liver Cancer pipeline landscape. It covers the Liver Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Liver Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download…
Long Island DWI Lawyer Jason Bassett Explains How Rising BAC Science Can Challen …
Long Island DWI lawyer Jason Bassett (https://jbassettlaw.com/rising-bac-the-science-how-to-argue-it/) of the Law Offices of Jason Bassett, P.C. is drawing attention to a scientific defense that can be critical in New York drunk driving cases. The rising blood alcohol concentration (BAC) defense examines how alcohol continues to be absorbed into the bloodstream even after a person has stopped drinking and driving. When used correctly, this argument can challenge the reliability of breath or…
Relapsing Refractory Multiple Myeloma Pipeline Outlook Report 2025: Key 55+ Comp …
DelveInsight's, "Relapsed/Refractory Multiple Myeloma Pipeline Insight, 2025" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Relapsed/Refractory Multiple Myeloma pipeline landscape. It covers the Relapsing Refractory Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsing Refractory Multiple Myeloma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Diabetic Macular Edema Pipeline Outlook Report 2025: Key 45+ Companies and Break …
DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
More Releases for Vitiligo
Organic Care Australia Introduces 'Vitiligo Organics' - A Revolutionary Herbal T …
Image: https://www.getnews.info/uploads/39ec7fd227c4937add1acccc27f32c1b.jpg
Organic Care Australia proudly announced the launch of 'Vitiligo Organics' in 2009, a revolutionary herbal treatment that promises new hope for individuals living with vitiligo, a condition characterized by the loss of skin pigmentation resulting in white patches. This innovative product represents a significant breakthrough in the management of vitiligo, offering a natural, effective solution for those who have long sought an alternative to conventional treatments.
Vitiligo impacts millions worldwide,…
Vitiligo Treatment Market - Unleash Your True Colors: Breakthrough Vitiligo Trea …
Newark, New Castle, USA: The "Vitiligo Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Vitiligo Treatment Market: https://www.growthplusreports.com/report/vitiligo-treatment-market/7780
This latest report researches the industry structure, sales, revenue,…
Vitiligo - Drug Pipeline Landscape, 2022
Vitiligo is a chronic disorder that causes patches of skin to lose pigment or color, when melanocytes are attacked and destroyed, causing the skin to turn a milky-white color. There are two types of vitiligo such as nonsegmental or generalized vitiligo and segmental vitiligo. Nonsegmental or generalized vitiligo happens when the white patches appear symmetrically on both sides of body, such as on both hands or both knees. Segmental vitiligo…
Vitiligo Treatment Market: Rising Impressive Business Opportunities Analysis For …
Vitiligo Treatment Market Report 2022: Industry aims to provide an overview of the industry through detailed market segmentation. The report offers thorough information about the overview and scope of the market along with its drivers, restraints, and trends. This report is designed to include both qualitative and quantitative aspects of the industry in each region and country participating in the study.
Get a Sample PDF of the Report @ https://impeccablemarketresearch.com/enquiry/request-sample-pdf/14636671?utm_source=Openpr&utm_medium=Shubhamko
…
Vitiligo Skin Disorder
Vitiligo Skin Disorder
Vitiligo skin disorder is a skin condition in which white patches on the skin are formed due to malfunctioning of melanocytes, cells that promote pigmentation. http://www.curevitiligooil.com/Vitiligo-Skin-Disorder.htmlThe start of this disease and the grimness of pigment loss vary from person to person. People who have light skin usually witness the loss of pigment in summers because the contrast between depigmented skin and sunburned skin appears distinctive. On the other…
Vitiligo Symptoms
Vitiligo produces macules which are small areas of different skin color. The skin disorder may also produce patches which are flat, pale or white and can't be felt with fingers. (http://www.curevitiligooil.com/Vitiligo-Symptoms.html). These marks frequently expand to form very large, irregularly-shaped areas with no pigmentation. Typically, these are painless and do not itch. The cause of vitiligo symptoms is not known, but autoimmunity may be a factor. Since it is a…
